Inhibikase Therapeutics, Inc. Annual Report: A Simple Guide

I’m breaking down Inhibikase Therapeutics’ performance over the past year. My goal is to turn complex filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Inhibikase is a clinical-stage pharmaceutical company. They are still in the "lab phase," meaning they do not sell products to the public yet.

Their primary focus is Pulmonary Arterial Hypertension (PAH), a life-threatening condition involving high blood pressure in the lungs. Their lead drug, IKT-001, is a new version of a known drug called imatinib. While imatinib treats certain cancers, it often causes severe stomach issues at the high doses needed for PAH. Inhibikase’s version uses a special delivery system to bypass the stomach. This could allow patients to take the high doses needed to stop the disease from progressing.

2. Financial performance

Because they have no products on the market, they have no sales revenue. For the year ending December 31, 2024, the company lost about $36.8 million, with $25.4 million going toward research and development.

As of their latest filing, they held about $14.2 million in cash. With a monthly burn rate of roughly $2.5 million to $3.0 million, the company will need to raise additional capital to continue operations. As of mid-2025, the company was valued at approximately $127.3 million, a figure driven by market expectations for their future clinical success rather than current profitability.

3. Major wins and strategic shifts

The company made two big moves this year to sharpen their focus:

• Acquisition: In February 2025, they bought CorHepta Pharmaceuticals for $15 million in stock. This gave them the technology and rights to pivot their entire pipeline toward the high-growth PAH market.
• Refocusing: They stopped working on their Parkinson’s disease drug, risvodetinib, to focus all their resources on the PAH program. They licensed that project to another company, which could bring in up to $47.5 million in future payments if that drug succeeds.

4. The "Dilution" risk

The company sells new shares to investors to fund their operations. Throughout 2024 and early 2025, they used "at-the-market" offerings to raise cash. Every time they create new shares, your ownership percentage in the company is reduced. Because they are running an expensive Phase 3 trial, they will likely need to issue more shares or take on debt until they have a product to sell.

5. Future outlook: The "IMPROVE-PAH" Trial

The company is now focused on their Phase 3 trial, "IMPROVE-PAH," which is testing the drug at 180 sites worldwide with a target of 300 to 400 patients.

• The Goal: Prove the drug works better than a placebo at helping patients walk further in six minutes, which is the standard test for regulatory approval.
• The Competition: They are entering a market where Merck’s Winrevair has set a high bar. Inhibikase believes their oral pill, IKT-001, will compete well because it is easier to take than current injectable treatments.

Final Thought for Investors: Inhibikase is a high-risk, high-reward investment. The company’s value rests almost entirely on the results of the IMPROVE-PAH trial. If the trial succeeds, it could be a significant milestone for the company; if it fails, the company faces a very difficult road. When considering an investment, weigh the potential of their oral PAH treatment against the reality of their current cash needs and the likelihood of future share dilution.